Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100
(NYSE: ANRO) Delayed: 24.44 +1.51 (6.59%)
Previous Close $22.93    52 Week High $ 
Open $22.32    52 Week Low $ 
Day High $25.80    P/E N/A 
Day Low $22.32    EPS $ 
Volume 404,563